Benchmark starts CapsoVision with a Speculative Buy as CapsoCam Plus takes share

As previously reported, Benchmark initiated coverage of CapsoVision (CV) with a Speculative Buy rating and $5 price target The company’s CapsoCam Plus for small bowel applications has been gaining market share with its differentiated features, notes the analyst, who sees the potential for additional long-term growth coming from international expansion and the ability to screen for multiple cancers simultaneously. The company will soon introduce AI-assisted image reading and a version of the product designed for the large intestine, the analyst noted.